Alliance Boots to buy 12% stake in Nanjing Pharmaceutical

By Admin
Share
Alliance Boots said it will buy a 12% stake in Chinas Nanjing Pharmaceutical Co, the news reports said. The European drugstore chain said it will compl...

Alliance Boots said it will buy a 12% stake in China’s Nanjing Pharmaceutical Co, the news reports said. The European drugstore chain said it will complete the transaction through a private placement of around 56 million pounds ($90.8 million).

The stake acquisition will make Alliance Boots Nanjing Pharmaceutical’s second-largest shareholder with management representation.

The move marks the latest foreign acquisition in China’s healthcare sector, as the investors expect further government reforms to boost the private-sector involvement.

The private equity companies including Carlyle Group and RRJ Capital have been active investors in the country’s healthcare sector this year. Shanghai-listed Nanjing Pharmaceutical reported sales of about 20 billion yuan ($3.2 billion) last year and operates in 12 cities across China.

Alliance Boots had a joint venture in China since 2008 with Guangzhou Pharmaceuticals Corp. U.S.-based pharmacy giant Walgreen Co has about 45% stake in Alliance Boots through a $6.7 billion deal struck in June. Both of them together operate over 11,000 drugstores in U.S., Europe, and Asia under the Walgreens and Boots names.

Alliance Boots is a well-known pharmacy-led health and beauty group that delivers a wide range of products and services to its customers. Nanjing Pharmaceutical Company is listed on the Shanghai Stock Exchange and is the fifth largest pharmaceutical wholesaler in China. 

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma